A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Inclusion Criteria:

• Participants in Part 1 must have histologic or cytologic confirmation of non-smallcell lung cancer (NSCLC), metastatic triple negative breast cancer (mTNBC), squamouscell carcinoma of head and neck (SCCHN), pancreatic adenocarcinoma (PAAD), renalcell carcinoma (RCC), microsatellite-stable colorectal carcinoma (MSS CRC), orsarcoma, that is advanced (metastatic, recurrent, and/or unresectable) withmeasurable disease per RECIST v1.1. In Part 2, only participants with histologicconfirmation of advanced NSCLC or mTNBC with measurable disease per RECIST v1.1 areeligible.

• In Part 2, archival biopsy collected within 3 months of screening with nointervening therapy (formalin-fixed, paraffin embedded [FFPE] blocks or a minimum of 20 freshly cut unstained FFPE slides with an associated pathological report) orfresh biopsy collection at Screening and fresh biopsy collection at cycle 3 day 1 (C3D1) (± 5 days) are mandatory, while it is strongly encouraged but optional atprogression. Therefore, the participant in Part 2 must have a suitable tumor lesionfor the biopsy procedure, as judged by the investigator, in order to be eligible forthe study.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• Participants resistant/refractory to or intolerant of existing standard therapiesknown to provide clinical benefit (in addition, participants with NSCLC must beresistant or refractory to anti-PD-(L)1-based immunotherapy)

Exclusion Criteria:

• Participants with primary central nervous system (CNS) disease, or tumors with CNSmetastases as the only disease site, will be excluded. Participants with controlledbrain metastases, however, will be allowed to enroll. Controlled brain metastasesare defined as no radiographic progression for at least 4 weeks following radiationand/or surgical treatment (or 4 weeks of observation if no intervention isclinically indicated), no longer taking steroids for at least 2 weeks prior to firstdose of study intervention, and with no new or progressive neurological signs andsymptoms.

• Participants with a condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalent) within 14 days or other immunosuppressivemedications within 30 days of randomization. Inhaled or topical steroids and adrenalreplacement steroid doses > 10 mg daily prednisone equivalent are permitted in theabsence of active autoimmune disease.

• Participants with concurrent malignancy or history of prior malignancy active within 2 years (except history of early-stage basal/squamous cell skin cancer ornon-invasive or in situ cancers who have undergone definitive treatment) areexcluded unless treatment was completed at least 2 years before randomization andthe participant has no evidence of disease.

• Participants with NSCLC with known or not tested for epidermal growth factorreceptor (EGFR) or V-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600Emutations, or anaplastic lymphoma kinase (ALK) or receptor tyrosine kinase (ROS1)translocations sensitive to available targeted inhibitor therapy

Other protocol-defined inclusion/exclusion criteria apply.